Chronic Myelomonocytic Leukemia Terminated Phase 2 Trials for Deferasirox (DB01609)

Also known as: Chronic myelomonocytic leukaemia / Chronic myelomonocytic leukemia with failed remission / Leukemia, Myelomonocytic, Chronic

IndicationStatusPhase
DBCOND0028572 (Chronic Myelomonocytic Leukemia)Terminated2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01159067Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron OverloadSupportive Care